Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4204680 | 0.84 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4198063 | 0.79 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4205210 | 0.76 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Methane SCHEMBL4199208 | 0.75 | CHRM2 (0.51) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4206274 | 0.75 | CHRM2 (0.53) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4198068 | 0.69 | CHRM2 (0.70) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4209242 | 0.69 | CHRM2 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4199213 | 0.69 | CHRM2 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13495110 | 0.67 | CHRNA7 (0.53) | CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL3218495 | 0.67 | LSS (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | disclosed |
| EP-1905771-A2 | Quinuclidine derivatives and their use | NeuroSearch A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | ACHE, CHRNA5, CHRNA3 | CHRM1 28/4885CHRM3 10/4885CHRM2 20/4885 |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | ACHE, CHRNA5, CHRNA3 | CHRM1 28/4885CHRM3 10/4885CHRM2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.